G. Steven Burrill
Chief Executive Officer

Ann F. Hanham
Managing Director

Bryant E. Fong
Managing Director

Benjamin P. Chen
Managing Director

Andrew Yi Zhang
Manager, Greater China

Marietta Wu
General Manager, Greater China

Marietta Wu
General Manager, Greater China

Greater China, with its tremendous cost advantages, a rapidly growing domestic market and quickly advancing science and technology base, is becoming an important force in the global life sciences industry. Burrill & Company, with its vision that Greater China is becoming a leading global pharmaceutical development and manufacturing center, has established the BGC to "bridge" the life science industries in Greater China and the Western world. BGC leverages its network and resources in both sides of the Pacific to capture China-related venture capital investing and merchant banking opportunities.

BGC brochure (PDF)

The Following Are Presentations from Our Recent China Life Sciences Partnering Forums

• Healthcare and Lifesciences – Changing the World Everyday,
  Dr. Caroline A. Kovac, General Manager, IBM Healthcare and Life Sciences
  
  
• Legal Impact of New Safe Rules on Offshore Financing by PRC Residents, Charles Li, Attorney at Law & Partner, Han Kun Law Offices
  
  
• Accelerate Development by Leveraging China Resources, Guo-Liang Yu, Ph.D., Chairman, President and CEO, Epitomics
  
  
• The Challenges and Opportunities of China Pharmaceutical Industry, Dr. Wei, Huacheng, Chairman of Beijing Pharmaceutical Group Co. Ltd
  
  
• Intellectual Property Rights: Prospects and Challenges in China, Jason Ma, Heller Ehrman,
  
  
• Bridging Across the Pacific Ocean, Dr. Jonathan Wang, Ph.D., General Manager Burrill Greater China Group (BGC), Burrill & Company
  
  
• Investing the China Life Sciences Industry: Opportunities and Challenges, Haitao Jin
  
  
• Transpacific Partnering: Pharma's Perspective, Dr. Larry Ng, M.D., Lilly,
  
  
• Building An Innovative Path for Pharmaceutical R&D in China, Ling Chen, M.D., Ph.D., Director General, Guangzhou Institute of Biomedicine and Health (GIBH), Chinese Academy of Sciences
  
  
• Presentation for Panel Discussion, Lucy Lu, VP, Technology Management.Head, US Chief Technology Office
  
  
• Investment Environment and Development Planning for Shenzhen Biomedicine Industry, Luming Zhou
  
  
• Drug Development in China: Opportunities and Challenges – A Clinical Trial Perspective, Mark Engel, President and CEO, Excel PharmaStudies
  
  
• Drug Development in China: Opportunities and Challenges – Cross Border Bio-Partnering and Investing, Mark Engel, President and CEO, Excel PharmaStudies
  
  
• China IP Issues, Michael Wise
  
  
• Presentation for Panel Discussion, Ming Pang
  
  
• Tales of an Entrepreneur: Starting a Company, Identifying Opportunity, Saving the World, Dr. Ronald Cape
  
  
• Presentation for Panel Discussion, Shuwei Yang
  
  
• Can Chinese Biotech Catch the Opportunity in Global R&D?,
  Dr. Xian-Ping Lu, Ph.D., CEO & CSO, Chipscreen Biosciences Ltd.